Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation reports developments across its biopharmaceutical business in cardiometabolic and orphan lung diseases. Company updates center on commercial products such as Afrezza, an inhaled insulin for diabetes, and Furoscix, a furosemide injection for fluid overload in heart failure and chronic kidney disease, as well as financial results, product demand, launch infrastructure and capital-structure actions.
MannKind news also covers dry powder inhalation programs and drug-device combinations, including work using its Technosphere platform. Recurring topics include Afrezza clinical and real-world data, Furoscix device and regulatory updates, Nintedanib DPI for idiopathic pulmonary fibrosis, ralinepag DPI collaboration activity with United Therapeutics, and other pipeline decisions affecting inhaled therapies.
MannKind Corporation (Nasdaq: MNKD) has secured a strategic financing agreement worth up to $500 million with Blackstone. The deal includes a $75 million initial term loan at closing, a $125 million delayed draw term loan available for 24 months, and an additional $300 million uncommitted DDTL.
The non-dilutive financing, maturing in August 2030, bears interest at SOFR plus 4.75%. The funds will support MannKind's growth initiatives, including the commercial team expansion for Afrezza's potential pediatric indication, pipeline advancement, and business development opportunities.
MannKind Corporation (Nasdaq: MNKD) reported strong Q2 2025 financial results with total revenues of $76.5 million, up 6% year-over-year. The company achieved net income of $0.7 million in Q2 2025, compared to a net loss of $2.0 million in Q2 2024.
Key highlights include the submission of an sBLA for Afrezza in pediatric patients, with a review decision expected in early Q4 2025. The company's pipeline is advancing with the ICoN-1 trial for inhaled clofazimine (MNKD-101) enrollment ahead of schedule, and plans to initiate a Phase 2 trial for nintedanib DPI (MNKD-201) in IPF by year-end 2025.
Revenue growth was driven by a 22% increase in royalties from Tyvaso DPI sales and a 13% increase in Afrezza revenue to $18.3 million. The company maintained a strong financial position with $201.2 million in cash and investments as of June 30, 2025.
MannKind Corporation (NASDAQ: MNKD) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, before the market opens. The company will host a conference call and webcast at 9:00 a.m. Eastern Time to discuss the results and provide business updates.
The presentation will be accessible through MannKind's investor relations website, with a replay available for approximately 90 days after the event.
MannKind Corporation (MNKD) is partnering with NTT INDYCAR SERIES driver Conor Daly for a special event during the Chevrolet Detroit Grand Prix week. The event, scheduled for May 29, 2025, at Full-Throttle Adrenaline Park in Novi, MI, will feature Daly sharing his experience living with Type 1 diabetes and racing go-karts with local youth.
Daly, diagnosed with T1D at age 14, is the only known U.S. professional racing driver competing full-time with the condition. He will drive the No. 76 "Tired of Pricks?" Chevrolet for Juncos Hollinger Racing at the Detroit Grand Prix. His notable achievements include a career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and becoming the first driver to compete in both NASCAR and IndyCar on consecutive Texas weekends in 2023.
MannKind Corporation (MNKD), a company specializing in inhaled therapeutic products for endocrine and orphan lung diseases, has announced its participation in two upcoming investor conferences. CEO Michael Castagna and CFO Chris Prentiss will present at:
- RBC Capital Markets 2025 Global Annual Healthcare Conference on Tuesday, May 20 at 8:00 a.m. ET
- Jefferies Global Healthcare Conference on Thursday, June 5 at 2:35 p.m. ET
Both conferences will be held in New York City. Live audio webcasts will be available on MannKind's investor relations website, with recordings accessible for approximately 90 days after the events.
MannKind Corporation (MNKD) has scheduled its Q1 2025 financial results announcement for May 8, 2025, before market open. The company will host a webcast at 9:00 a.m. Eastern Time featuring CEO Michael Castagna and CFO Chris Prentiss to discuss the quarterly results and provide a business update. The webcast will be available through MannKind's investor relations website, with a replay accessible for approximately 90 days following the call.
MannKind (MNKD) has announced a continued partnership with Juncos Hollinger Racing (JHR) driver Conor Daly for the 2025 NTT INDYCAR Series season. Daly, the only known U.S. pro racing driver competing full-time with type 1 diabetes, will showcase a striking 'Tired of Pricks?' livery at the Acura Grand Prix of Long Beach on April 13.
MannKind will serve as primary sponsor for the No. 76 Chevrolet at three major events: Long Beach Grand Prix, Detroit Grand Prix (June 1), and World Wide Technology Raceway (June 15). The company will maintain an associate sponsorship throughout the 2025 season. The partnership aims to raise awareness about diabetes and innovative treatment options through InhaleMyInsulin.com.
Daly's impressive racing career includes notable achievements such as his career-best 6th place finish at the 2022 Indy 500, leading the most laps at the 2021 Indy 500, and securing JHR's first IndyCar podium at Milwaukee in 2024.
MannKind (MNKD) will present five studies on inhaled insulin at the 18th International Conference on Advanced Technologies and Treatments for Diabetes in Amsterdam, March 19-22, 2025. The presentations will showcase data from the INHALE-1 pediatric and INHALE-3 adult studies of Afrezza®.
Key presentations include research on pulmonary inhaled insulin, pediatric applications, sustained benefits from the INHALE-3 extension study, post-prandial glucose excursion comparisons between youth and adults with Type 1 diabetes, and a comparison study of inhaled Technosphere insulin plus insulin degludec versus usual care in adults.
The company anticipates filing a supplemental New Drug Application (sNDA) for Afrezza in the pediatric population in 2025. MannKind will also host booth #40 in the exhibit hall for scientific exchange with their Clinical Education Team.